Akebia Therapeutics Updates License Agreement with Medice for Vafseo Supply and Manufacturing
Akebia Therapeutics Inc. has amended its License Agreement with MEDICE Arzneimittel Pütter GmbH & Co. KG for the development and commercialization of Vafseo for anemia in chronic kidney disease patients in Europe and other regions. Akebia will supply vadadustat drug substance to Medice, which will manufacture Vafseo tablets. Any resulting know-how or patent rights will be owned by Akebia. The amendment will be filed with the Annual Report on Form 10-K for 2025.
Akebia Therapeutics Inc. announced an amendment to its existing License Agreement with MEDICE Arzneimittel Pütter GmbH & Co. KG regarding the development and commercialization of Vafseo for anemia in chronic kidney disease patients in Europe and certain other countries. Under the amendment, Akebia will supply vadadustat drug substance to Medice, which will have the right to manufacture Vafseo tablets using the supplied substance. Any know-how or patent rights resulting from Medice’s manufacture of Vafseo tablets will be owned by Akebia. The company plans to file the amendment as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001517022-25-000048), on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
